Responsabile del Centro Oncologico degli Organi ORL – Il Dott. Meyer è specializzato nel cancro alla tiroide presso l'Ospedale Asklepios St. Georg.
Il Professor Keil è specializzato in imaging avanzato e radiologia interventistica per il cancro alla tiroide, portando oltre 18 anni di diagnostica di precisione al Medical Center di Solingen.
Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.
Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Professor Kyzas completed his PhD thesis in H&N Cancer with Honours (Αριστα), producing several highly cited influential publications. He has published > 70 scientific papers in high impact journals and has > 6000 citations.
Following his studies, Professor Kyzas has undertaken postgraduate training in the UK and was successful in securing a very competitive training post in the UK Higher Specialty Training Programme for Oral and Maxillofacial Surgery. He was trained in some of the biggest University Teaching hospitals in the North West of the UK. He has been awarded the Certificate of Completion of Training (CCT) in Oral and Maxillofacial Surgery by the General Medical Council (GMC). Subsequently, he was successful in securing one of the very few and prestigious UK-wide Training Interface (TIG) Fellowships in Head and Neck Surgical Oncology. He has successfully completed his fellowship and was awarded the subspecialty of Head and Neck Surgery by the Joint Committee of Surgical training (JCST).
In 2014 he has been appointed as a permanent substantive Consultant in Oral and Maxillofacial/Head and Neck Surgery in Manchester. He has treated hundreds of patients with Head and Neck cancer, offering state of the art major ablative and reconstructive surgery. He specialises in microvascular free tissue transfer and he has introduced and developed the 3D printer – personalised planning (PSP) reconstructive surgery in his hospital. He led his unit to become a reference centre by having the highest number of successful 3D PSP cases in the UK. Besides head and neck cancer, Professor Kyzas offers treatment to patients with facial skin cancer, oral and maxillofacial trauma, dentoalveolar surgery, orthognathic surgery, salivary gland diseases, facial cosmetic surgery, surgery of the temporomandibular joint, and anything else within the broad spectrum of Oral and Maxillofacial Surgery. He has performed many thousands of surgical procedures and has vast experience in any oral and maxillofacial condition. He has a special interest in the use of laser for oral pathologies and he is the Principal Investigator for an international trial examining the effectiveness of Transoral Laser resection in Ηead and Νeck Cancer. He is a certified microvascular surgeon and has accreditation in advanced trauma life support (ATLS).
Just before the covid pandemic, Professor Kyzas was presented with a unique opportunity to lead on the development of a Head and Neck Cancer Service in Lancashire. Professor Kyzas and his team managed to establish the service within months, and throughout the challenging covid period. The ELHT H&N Unit now produces oncological outcomes that compare favourably with any major H&N unit worldwide. Professor Kyzas has been appointed as the Clinical Director for all cancer services in ELHT, covering population of > 1M people.
In 2021, Professor Kyzas has been awarded the highly prestigious Bronze National Clinical Excellence Award for his overall services in the NHS. He was the youngest consultant to achieve this award and the only Cypriot OMFS surgeon ever to be considered for one.
Professor Kyzas has a long history of involvement in medical research. In 2007 he has completed his PhD thesis which has resulted in several highly cited publications in some of the most prestigious medical journals. He has participated in international collaborations for the improvement of medical research (http://progress-partnership.org/publications) and some of his papers have had a significant impact in improving research methodology. He has given several invited international lectures, and he has presented in national and international conferences. He has been a panel member for the selection committees for trainees in every level in oral and Maxillofacial Surgery in the UK. He is a regular peer-reviewer for many medical journals. He is the Lead trainer for the TIG H&N fellowship for his hospital and the Research Lead for his Deanery. He participates actively in Clinical Research, and he is the Principal Investigator for many clinical trials. He is a faculty member for the «Head and Neck resection tactics and free flap» course run by the Royal College of Surgeons of Edinburgh. He offers themed training in Head and Neck Oncological Surgery to medical students. In 2018 he was awarded the «Surgical Educator Excellence Award» by Health Education North West (HEENW). In the same year, he was nominated as doctor of the year in Northern Care Alliance.
Professor Kyzas is the Chief Investigator of the MANTRA trial, a UK multicentre RCT with multimillion pounds NIHR funding, launched in July 2023. This is the biggest randomised controlled trial ever to be performed in the specialty of OMFS.
As a result of his outstanding clinical and research/academic achievements, Professor Kyzas has been appointed as a visiting Professor in OMFS H&N Surgery at Edge Hill University
In 2018 Professor Kyzas was elected as the Deputy Editor for the British Journal of Oral and Maxillofacial Surgery (BJOMS). In January 2024, Professor Kyzas started his role as Editor in Chief for the BJOMS. This is the first time that a Greek Cypriot has ever been chosen for this highly prestigious role. Professor Kyzas sits in the council of the British Association of Oral and Maxillofacial Surgeons (BAOMS).
Professor Kyzas is a fully accredited medical expert witness and has provided hundreds of medical expert negligence reports (πραγματογνώμονας). In June 2024, Professor Kyzas has completed his Degree in Law with Honours (Άριστα), becoming a member of a very prestigious club of medical professionals with an active interest and certified knowledge in medicolegal practice.
Professor Kyzas is a fully accredited Oral and Maxillofacial Surgeon on the specialist register of the General Medical Council (GMC) UK, the Cyprus Medical Association (Cyprus), and the Cyprus Dental Association (Cyprus). In addition, he is also fully recognised and registered as Oral Surgeon by the General Dental Council (GDC) UK. He is a fellow of the Royal College of Surgeons (FRCSEd), member of the Faculty of Surgical Trainers (MFSTEd), fellow of the British Association of Oral and Maxillofacial Surgeons (BAOMS), member of the Hellenic Society of Head and Neck Oncology (HeSHNO) and member of the European Association of Craniomaxillofacial Surgery (ECAMFS).
Education
Experience
Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.
He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.
Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.
Education
Ondokuz Mayıs University Faculty of Medicine (1991)
KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)
Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)
Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)
Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)
Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.
Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).
Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.
Education and Training:
Graduated in Medicine and Surgery from the University of Navarra (1985).
Completed residency in Oncology in 1987.
Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).
Professional Experience:
Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).
Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).
Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).
Head of the Oncology Department at Hospital General de Villalba (2014–2019).
Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.
Certifications and Training:
Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.
Research and Publications:
Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.
Dr. Felix Dobritoiu is a thoracic surgeon at Ponderas Academic Hospital. He specializes in minimally invasive and robotic procedures for adults and children. He performs robotic thoracic surgery with the da Vinci Xi system. He also uses video-assisted thoracoscopic surgery (VATS), including uniportal VATS. These methods use small incisions for faster recovery.
His practice includes mediastinoscopy and bronchoscopy. He performs complex lung and mediastinal resections. He also offers sternochondroplasty (Nuss and reversed Nuss). In selected cases, he can perform minimally invasive procedures without postoperative pleural drainage.
Oncology:
Head and neck tumors
Thyroid cancer
Personalized biological and immunotherapy
Treatment of recurrent cancer and spinal metastases
Radiotherapy
1998 — Graduated from the Faculty of Medicine at the Hebrew University (Jerusalem, Israel).
2016 — Six-month advanced training course in radiosurgery with a special focus on modern methods of focused radiotherapy for spinal and malignant thyroid tumors at Memorial Sloan Kettering Cancer Center (New York, USA).
1998–1999 — Internship at Hadassah University Hospital (Jerusalem, Israel).
1999–2005 — Specialization in the Department of Otolaryngology and Head & Neck Surgery at Rabin Medical Center (Petah Tikva, Israel).
2005–2009 — Specialization in oncology and radiotherapy at the Davidoff Cancer Center (Rabin Medical Center).
2006–2008 — Fellowship at the University of Michigan (Ann Arbor, USA) in multidisciplinary cancer treatment.
2008 — Fellowship in head and neck tumor brachytherapy at Beth Israel Medical Center (New York, USA).
2009–2012 — Head of the Head and Neck Oncology Clinic at the Davidoff Cancer Center.
2013–2019 — Chief of the Head and Neck Oncology Division and Deputy Head of the Radiotherapy Department at the Davidoff Cancer Center.
Since 2019 — Director of the Oncology Department and Sharett Cancer Institute at Hadassah University Hospital.
2017: Oticon Medical Scientific Center Copenhagen Denmark.
2016: ICLO Teaching Center New Endoscopic Approaches to Lateral Skull Base, Inner Ear and Cerebello-Pontine Angle, Verona Italy
2016: World Hearing Center, Institute of Physiology and Pathology of Hearing, Warsaw,Poland
2015: Cochlear Science and Research Center Berlin Germany.
2014: Cochlear implant Center Medel Company Innsburck, Austria.
2014: Hannover Medical School. Clinic for Laryngology, Rhinology and Otology, Hannover, Germany
2014: Academy of Hearing Aid Acoustics (Akademie für Hörgerate-Akustik), Lübeck, Germany.
2013: International European Sialendoscopy Training Center, Geneva, Switzerland.
2012: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2012: University clinic of ORL, Head and Neck Surgery, Bern, Switzerland.
2011: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2007: The Ohio State University, Medical Faculty, Department of Otolaryngology, Division of Otology and Neurotology. Columbus, Ohio, USA.
2006: University of Würzburg, Department of Otolaryngology, Division of Otology and Neurotology. Würzburg, Germany.
1999-2003 İnönü Üniversitesi Tıp Fakültesi Kulak Burun Boğaz Anabilim Dalı
1993-1999 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
Turkish Otorhinolaryngology and Head and Neck Surgery Association
Turkish Otorhinolaryngology and Head and Neck Surgery Foundation
Turkish Rhinology Society
Tigris-Euphrates Basin Otorhinolaryngology and Head and Neck Surgery Association
Gaziantep Otorhinolaryngology Association
Turkish Otorhinolaryngology and Head and Neck Surgery Qualification Board
Turkish Otology Association
Malatya Otorhinolaryngology Association
American Academy of Otolaryngology Head and Neck Surgery
Mediterranean Society of Otology and Audiology
International Vertigo Association
Specializations
Cancer Surgery
Pancreatic Surgery
Bile Duct Surgery
Bariatric Metabolic Surgery
Oncological Surgery
Breast Surgery
Gastric cancer
Colon cancer
Thyroid Cancer
Obesity Surgery
Diabetes Surgeries
Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.
She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.
Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).
She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).